These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35067672)

  • 1. Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion.
    Ni F; Yin ETS; Zhou L; Zhao H; Luo Y; Shi J; Hu Y; Huang H
    Bone Marrow Transplant; 2022 Feb; 57(2):326-328. PubMed ID: 35067672
    [No Abstract]   [Full Text] [Related]  

  • 2. HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation.
    Jin X; Cao Y; Wang L; Sun R; Cheng L; He X; Xiao X; Jiang Y; Li Q; Zhang H; Lu W; Lyu C; Jiang Y; Meng J; Zhao M
    Leukemia; 2020 Mar; 34(3):909-913. PubMed ID: 31628429
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
    Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells.
    Mikhailova E; Illarionova O; Shelikhova L; Zerkalenkova E; Molostova O; Olshanskaya Y; Novichkova G; Maschan A; Maschan M; Popov A
    Haematologica; 2022 Apr; 107(4):970-974. PubMed ID: 34911282
    [No Abstract]   [Full Text] [Related]  

  • 5. [Chimeric antigen receptor (CAR) T cells targeting CD19 for acute lymphoblastic leukemia].
    Takahashi Y; Nishio N
    Rinsho Ketsueki; 2023; 64(9):1184-1191. PubMed ID: 37899199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation.
    Xu Q; Xu H; Xue L; Wang M; Pan G; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Xu H; Liu X; Zhu X; Sun Z; Yang L; Wang X
    Chin Med J (Engl); 2022 Jan; 135(1):98-100. PubMed ID: 33967196
    [No Abstract]   [Full Text] [Related]  

  • 7. Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia.
    Zhao X; Wu H; Cheng Y; Xu Z; Chen Y; Chang Y; Wang Y; Zhang X; Xu L; Huang X
    Chin Med J (Engl); 2023 Aug; 136(16):2011-2013. PubMed ID: 37462037
    [No Abstract]   [Full Text] [Related]  

  • 8. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
    Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
    J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Yao Z; Gu B; Zhang Y; Qi J; Chen J; Xu Y; Chen F; Ma X; Miao M; Xue S; Qiu H; Tang X; Han Y; Chen S; Sun A; Yu L; Wu D; Wang Y
    Bone Marrow Transplant; 2023 Jan; 58(1):103-105. PubMed ID: 36253466
    [No Abstract]   [Full Text] [Related]  

  • 11. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.
    Zhang C; Kong PY; Li S; Chen T; Ni X; Li Y; Wang M; Liu Y; Gao L; Gao L; Peng XG; Sun AH; Wang P; Yang Z; Zhang X; Qian C
    J Immunother; 2018; 41(6):306-311. PubMed ID: 29864079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ
    Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
    Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
    Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Lymphoma Remission Confers a Leukemia-Free Survival Advantage.
    Summers C; Wu QV; Annesley C; Bleakley M; Dahlberg A; Narayanaswamy P; Huang W; Voutsinas J; Brand A; Leisenring W; Jensen MC; Park JR; Gardner RA
    Transplant Cell Ther; 2022 Jan; 28(1):21-29. PubMed ID: 34644605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the Role of Hematopoietic Cell Transplantation (HCT) for Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric Antigen Receptor T-Cell (CART) Therapy?
    Taraseviciute A; Broglie L; Phelan R; Bhatt NS; Becktell K; Burke MJ
    J Pediatr Hematol Oncol; 2019 Jul; 41(5):337-344. PubMed ID: 30973486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CAR-T therapy for adult B-cell acute lymphoblastic leukemia].
    Goto H
    Rinsho Ketsueki; 2023; 64(11):1432-1439. PubMed ID: 38072431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of allogeneic haematopoietic cell transplantation as consolidation after anti-CD19 CAR-T cell therapy in adults with relapsed/refractory acute lymphoblastic leukaemia: a prospective cohort study.
    Han S; Zhou L; Chen Y; Zhou X; Guo Z; Yang J; Jin B; Liu Y; Chang LJ; Li Y; Tu S
    Bone Marrow Transplant; 2022 Mar; 57(3):513-516. PubMed ID: 35058582
    [No Abstract]   [Full Text] [Related]  

  • 18. Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?
    Bouziana S; Bouzianas D
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):e183-e191. PubMed ID: 32304874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia.
    Wang J; Zhang X; Zhou Z; Liu Y; Yu L; Jia L; Yang J; Li J; Yu H; Li W; Liu G; Rui W; Zheng H; Zhao X; Lin X; Lu P
    Am J Hematol; 2022 Aug; 97(8):992-1004. PubMed ID: 35491511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report.
    Li Z; Meng F; Li J; Wu T
    Front Immunol; 2022; 13():931452. PubMed ID: 35903089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.